Almanac Health, Inc.

Almanac Health, Inc. , based in the US, provides advanced clinical AI solutions designed to enhance medical practice through evidence-based tools, improving decision-making and patient care for healthcare providers. Almanac Health, Inc. is a clinical AI platform founded in 2025, headquartered in Dover, US.

The company has undergone strategic pivots but remains focused on delivering AI technologies tailored for healthcare. The founder's details are not publicly disclosed. Almanac Health raised USD 10. 00 mn in a Seed funding round led by F-Prime Capital, with participation from General Catalyst Partners and Lightspeed Venture Partners.

This funding represents the total amount raised to date across two deals. Almanac Health operates a clinical AI platform that focuses on improving the practice of medicine through evidence-based solutions tailored for clinicians. The platform integrates seamlessly into healthcare workflows, enabling practitioners to leverage advanced AI tools that enhance decision-making and patient care. By partnering with health systems, Almanac Health ensures that its offerings meet the real-world needs of clinicians and patients.

The primary end-users of Almanac's platform include healthcare providers across various specialties, primarily in the United States and select international markets, reinforcing their commitment to clinical efficacy and institutional governance. Almanac Health generates revenue through structured partnerships and subscription-based models that cater to healthcare institutions. Transactions typically involve direct contracts with hospitals and clinics, allowing clients to subscribe to access the clinical AI platform and its associated services. These agreements may feature tiered subscription options that align with the size and specific needs of the healthcare provider, facilitating long-term relationships with healthcare providers seeking to adopt innovative AI solutions in their clinical practices.

Almanac Health is focused on designing and launching new products aimed at enhancing their clinical AI capabilities. The company plans to expand into additional markets, specifically targeting Europe and Asia by 2026. The recent funding of USD 10. 00 mn from the Seed round will be utilized to support product development and market entry strategies, ensuring that their solutions meet the evolving demands of healthcare providers globally.